Duffy Danielle, Rader Daniel J
Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Nat Rev Cardiol. 2009 Jul;6(7):455-63. doi: 10.1038/nrcardio.2009.94. Epub 2009 Jun 2.
Low levels of HDL cholesterol are a significant predictor of atherosclerotic cardiovascular events. HDL is believed to protect against atherosclerosis by promoting reverse cholesterol transport, and potentially through anti-inflammatory, antioxidative, antithrombotic and nitric oxide effects. The multiple mechanisms of action, as well as a limited ability to measure these properties, make HDL a complex therapeutic target, albeit one with immense potential for the treatment of patients with atherosclerosis. Here, we discuss new therapeutic strategies currently being developed, which have the potential to increase plasma levels of HDL cholesterol and/or improve HDL function.
高密度脂蛋白胆固醇水平较低是动脉粥样硬化性心血管事件的重要预测指标。人们认为高密度脂蛋白通过促进胆固醇逆向转运，以及可能通过抗炎、抗氧化、抗血栓形成和一氧化氮效应来预防动脉粥样硬化。其多种作用机制以及测量这些特性的能力有限，使得高密度脂蛋白成为一个复杂的治疗靶点，尽管它在治疗动脉粥样硬化患者方面具有巨大潜力。在此，我们讨论目前正在研发的新治疗策略，这些策略有可能提高血浆高密度脂蛋白胆固醇水平和/或改善高密度脂蛋白功能。
